Skip to main content

Table 1 Demography and clinical characteristics of polyarthritis patients (baseline and after 8 weeks of infliximab treatment)

From: Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients—immune-related candidate proteins affected by TNF blocking treatment

ID

Age

Sex

Diagnosis

Additional treatments

Baseline

After infliximab treatment

DAS28

ESR (mm)

CRP (mg/L)

TJC

SJC

DAS28

ESR (mm)

CRP (mg/L)

TJC

SJC

1

43

F

RA+

M, N, Pa

3.80

18

5.4

1

1

3.82

15

ND

1

0

2

34

F

RA

M, N, Pa

4.77

18

3.0

4

4

4.39

29

2.3

4

0

3

74

F

RA

M, Pr, Pa

7.50

90

93.3

13

12

6.67

50

43.3

13

11

4

35

F

JCA

M, Pr, N

4.10

11

7.6

7

4

2.96

10

7.4

4

0

5

41

F

JCA

M, Pr, Pa

2.35

10

4.0

0

0

ND

ND

0.5

ND

ND

6

26

F

AS

M, Pr, N

ND

90

56.5

ND

ND

ND

24

1.7

ND

ND

7

52

F

PsA

M, N

6.34

90

78.8

6

4

4.73

48

ND

4

2

Patients without paired CSF samples

 

 8

31

F

RA+

M, N, Pa

ND

41

19.8

15

15

ND

12

0.5

ND

ND

 9

51

F

RA+

M, A

5.94

30

15.6

12

3

ND

11

1.6

1

2

 10

61

F

PsA

M, N, Pa

5.51

63

28.6

2

4

ND

ND

0.9

0

0

  1. A azathioprine, AS ankylosing spondylitis, CRP high-sensitivity C-reactive protein, DAS28 Disease Activity Score 28, ESR erythrocyte sedimentation rate, F female, JCA juvenile chronic arthritis, M methotrexate, N non-steroidal anti-inflammatory drug, ND not determined, Pa paracetamol, Pr prednisolone, PsA psoriatic arthritis, RA rheumatoid factor negative rheumatoid arthritis, RA+ rheumatoid factor positive rheumatoid arthritis, SJC swollen joint count, TJC tender joint count